InsiderPulse
Dashboard

AXSM

Axsome Therapeutics, Inc.

Health CareRussell 2000

Axsome Therapeutics, Inc. insider trading

Axsome Therapeutics, Inc. files with the SEC as a Pharmaceutical Preparations company headquartered in New York, NY. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent AXSM insider transactions

7 insiders traded AXSM on the open market between Feb 26, 2026 and Sep 03, 2026 — 19 sales worth $61.1M, of which every one was pre-scheduled under a 10b5-1 plan.

Bought
—
Sold
$61.1M

19 of 19 on a 10b5-1 plan

Net
−$61.1M
Insiders
7

Open-market purchases (code P) and sales (code S) from Axsome Therapeutics, Inc.'s own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 22, 2026. The live dashboard shows new filings the moment they clear.

Every AXSM Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

AXSM insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 9 insiders traded AXSM on the open market: 3 purchases worth $200.5K and 60 sales worth $162.2M, 59 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 3 purchases ($200.5K) and 45 sales ($143.5M), by 8 insiders.

QuarterBoughtSold
Q2 2026—−$26.8M13 sales · all on a plan
Q1 2026—−$43.3M8 sales · all on a plan
Q4 2025—−$45.1M11 sales · all on a plan
Q3 2025+$200.5K3 buys−$28.3M13 sales · all on a plan
Q2 2025—−$11.7M11 sales · 10 on a plan
Q1 2025—−$2M2 sales · all on a plan
Q4 2024——
Q3 2024—−$5M2 sales · all on a plan
Largest purchase
+$101.8K of AXSM by Coleman Mark (Director) on Sep 08, 2025.
Largest sale
−$13.5M of AXSM by Tabuteau Herriot (Chief Executive Officer · Director) on Jan 05, 2026, under a 10b5-1 plan.

Open-market transactions through Jun 30, 2026most recent first

  • Tabuteau Herriot10b5-1

    Chief Executive Officer · Director

    −$6M

    Feb 02, 2026

    32,410 sh · $185.60

  • Pizzie Nick10b5-1

    Chief Financial Officer

    −$2.3M

    Jan 22, 2026

    12,000 sh · $187.92

  • Maizel Ari10b5-1

    Chief Commercial Officer

    −$1.4M

    Jan 21, 2026

    7,500 sh · $184.44

  • Tabuteau Herriot10b5-1

    Chief Executive Officer · Director

    −$5.3M

    Jan 07, 2026

    31,261 sh · $170.38

  • Tabuteau Herriot10b5-1

    Chief Executive Officer · Director

    −$5.1M

    Jan 06, 2026

    29,450 sh · $172.33

  • Tabuteau Herriot10b5-1

    Chief Executive Officer · Director

    −$13.5M

    Jan 05, 2026

    78,703 sh · $171.28

  • Saad Mark E10b5-1

    Director

    −$5.2M

    Dec 31, 2025

    31,346 sh · $165.18

  • Saad Mark E10b5-1

    Director

    −$1M

    Dec 31, 2025

    6,231 sh · $165.18

  • Tabuteau Herriot10b5-1

    Chief Executive Officer · Director

    −$1.6M

    Dec 04, 2025

    10,558 sh · $148.18

  • Tabuteau Herriot10b5-1

    Chief Executive Officer · Director

    −$3M

    Dec 03, 2025

    20,163 sh · $146.94

  • Tabuteau Herriot10b5-1

    Chief Executive Officer · Director

    −$7.1M

    Dec 02, 2025

    49,252 sh · $144.59

  • Tabuteau Herriot10b5-1

    Chief Executive Officer · Director

    −$2.9M

    Nov 05, 2025

    21,775 sh · $134.49

  • Tabuteau Herriot10b5-1

    Chief Executive Officer · Director

    −$6.8M

    Nov 04, 2025

    50,459 sh · $133.79

  • Tabuteau Herriot10b5-1

    Chief Executive Officer · Director

    −$12.1M

    Nov 03, 2025

    91,705 sh · $132.34

  • Tabuteau Herriot10b5-1

    Chief Executive Officer · Director

    −$1.5M

    Oct 08, 2025

    12,774 sh · $118.84

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

Axsome Therapeutics, Inc. company record

SEC industry classification
Pharmaceutical Preparations
Headquarters
New York, NY
Incorporated in
DE
Listed on
Nasdaq
SEC Central Index Key
0001579428

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought AXSM

What the stock actually did in the 90 days following each open-market purchase

Don't check AXSM — let it ping you

Get told the moment an insider moves on AXSM

Pro watches Axsome Therapeutics, Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add AXSM to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track AXSM on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read AXSM insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

KRYSRAREFOLDACADPTCTMEDPDNLIVEEVTEMALKSAPLSARVN
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are AXSM insiders buying or selling?
Between Feb 26, 2026 and Sep 03, 2026, 7 Axsome Therapeutics, Inc. insiders made no open-market purchases and 19 sales worth $61.1M, a net sale of $61.1M. 19 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much AXSM stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 9 Axsome Therapeutics, Inc. insiders made 3 open-market purchases worth $200.5K and 60 sales worth $162.2M. 59 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: 3 purchases ($200.5K) and 45 sales ($143.5M). The largest purchase was Coleman Mark buying $101.8K on Sep 08, 2025. The largest sale was Tabuteau Herriot selling $13.5M on Jan 05, 2026.
What was the largest recent AXSM insider trade?
Tabuteau Herriot (Chief Executive Officer · Director) sold $12M of AXSM stock on Jun 09, 2026 at about $241.01 a share, under a pre-scheduled 10b5-1 plan.
When did an insider last buy AXSM shares?
No open-market purchase by a Axsome Therapeutics, Inc. insider appears in the filings from Feb 26, 2026 to Sep 03, 2026 — every recorded open-market transaction in that period was a sale. Before that, the most recent purchase in SEC's data was Coleman Mark buying $101.8K on Sep 08, 2025.
Where does AXSM insider trading data come from?
From the Form 4 filings Axsome Therapeutics, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.